India, May 4 -- OneSource Specialty Pharma Limited, a specialty pharmaceutical CDMO, has announced that its partner Orbicular, along with a Canadian front-end partner, has secured approval from Health Canada for a generic version of Ozempic (semaglutide injection).
This marks the second approval for a generic semaglutide product in Canada, positioning OneSource's partners among the first generic entrants in a key global semaglutide market.
The development underscores a closely integrated model, with Orbicular leading product development and the technical program, while OneSource acted as the manufacturing partner, providing end-to-end capabilities for the Canadian filing. Commercial production will be supported from OneSource's US FDA-app...